1-(α-Hydroxy-ethyl)-4-<3-(2-trifluormethyl-phenothiazinyl-(10))-propyl>-piperazin | 2712-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 1-(α-Hydroxy-ethyl)-4-<3-(2-trifluormethyl-phenothiazinyl-(10))-propyl>-piperazin
• 英文别名: 1-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol；1-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol
• CAS: 2712-53-0
• 化学式: C₂₂H₂₆F₃N₃OS
• 分子量: 437.529
• InChiKey: UINQSZQZBZUOBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  乙醛 、 10-[3-(1-哌嗪基)丙基]-2-(三氟甲基)-10H-吩噻嗪 以 甲苯 为溶剂， 生成 1-(α-Hydroxy-ethyl)-4-<3-(2-trifluormethyl-phenothiazinyl-(10))-propyl>-piperazin
  参考文献：
  名称：

  4-{3-[10-(2-Trifluoromethyl)-phenothiazinyl]-propyl}-1-piperazine-ethanol¹ and Related Compounds. II²

  摘要：

  DOI：

  10.1021/ja01493a047

文献信息

• METHOD OF TREATING A PATHOLOGICAL SYNDROME
  申请人：Epshtein Oleg Iliich

  公开号：US20160229914A1

  公开（公告）日：2016-08-11

  A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.

  一种治疗与神经递质的细胞内信号传递相关的疾病或症状的方法，包括给予一种高度稀释的抗原抗体制剂，该抗原是一种能够影响神经受体的细胞内信号传递的分子，特别是多巴胺或血清素。
• Stabile, zur pharmazeutischen Verabreichung geeignete Emulsion, Verfahren zu deren Herstellung und Emulsion zur Anwendung als Arzneimittel
  申请人：KNOLL AG

  公开号：EP0456106A2

  公开（公告）日：1991-11-13

  Es wird eine stabile Wirkstoff-Emulsion vom Typ Öl-in-Wasser mit einem Phospholipid als Emulgator beschrieben, wobei der in der Lipidphase gelöste Wirkstoff eine oder mehrere basische Gruppen trägt, hydrophob und öllöslich ist, sowie einen pka-Wert von mindestens 7,5 besitzt, die wäßrige Phase auf einen sauren pH-Wert eingestellt ist und die disperse Phase nach Verdünnung der verabreichungsfertigen Emulsion auf einen Fettgehalt von 0,08 Gew.-% ein positives Zetapotential von mindestens +15, vorzugsweise aber +30 mV, ergibt.

  描述了一种以磷脂为乳化剂的稳定的水包油型活性物质乳液，其中溶解在脂相中的活性物质带有一个或多个碱性基团，疏水性和油溶性好，pka 值至少为 7.5，水相的 pH 值被调节为酸性，分散相在将即用型乳液稀释至脂肪含量为 0.08 重量%后，Zeta 电位至少为 +15 mV，但最好为 +30 mV。
• CURING METHOD FOR PATHOLOGIC SYNDROME AND A MEDICINAL PREPARATION
  申请人：Epshtein, Oleg Iliich

  公开号：EP1295606A1

  公开（公告）日：2003-03-26

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• Curing method for pathologic syndrome and medicinal preparation
  申请人：——

  公开号：US20030099636A1

  公开（公告）日：2003-05-29

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• Method of treating a pathological syndrome and a pharmaceutical agent
  申请人：Epshtein Iliich Oleg

  公开号：US20070224187A1

  公开（公告）日：2007-09-27

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.